NASDAQ NMS - GLOBAL MARKET · SUPN

-2.14% · -$0.9200 · Vol 1.2M

Market closed · last close 4:00 PM ET · price as of 16:29:34 ET

Supernus Pharmaceuticals Inc

Pharmaceuticals

$42.00

Card

Relationship Map

Follow $SUPN

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $SUPN by email

Veridion Score

BETALOW CONF · 6 of 6 factors measured

Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET · SUPN

Methodology

SUPN

Supernus Pharmaceuticals Inc

Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET

52/100

Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

52/ 100

Veridion Score

Middle range · LOW confidence · 6 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: LOW · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is SUPN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move SUPN next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Mar 3
CongressChecking access
Gilbert Ray Cisneros, Jr. purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 11
CongressChecking access
Gilbert Ray Cisneros, Jr. purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Oct 9
CongressChecking access
Gilbert Ray Cisneros, Jr. sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Mar 24
CongressChecking access
Gilbert Cisneros purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 23
CongressChecking access
Josh Gottheimer sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Nov 13
CongressChecking access
Gilbert Cisneros purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jul 17
CongressChecking access
Gilbert Cisneros purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 1
CongressChecking access
Gilbert Cisneros purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Supernus Pharmaceuticals Inc

PHARMACEUTICAL PREPARATIONS

Listed since

2012

Employees

778

Country

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$42.89

Day high

$42.89

Day low

$41.60

Previous close

$42.92

52W high

$57.00

-26.31% from high

52W low

$41.28

5% of range

Market cap

$2.5B

EPS

$-1.4500

Beta

-0.05

Shares out

58.2M

Volume

1.2M

1.92× rel vol

Avg volume

615.4K

VWAP

$42.01

Price history computed in-house

+0.87%

-11.48%

-5.36%

-8.77%

YTD

-15.49%

SMA 50 $45.60 · below

SMA 200 $48.34 · below

52W position 5%

SUPN overview

Veridion Score

Registered · 2026-09-18

6 of 6 factors measured

Latest receipt rows

Gilbert Ray Cisneros, Jr. · Purchase

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around SUPN.Congress disclosuresOpen receipt and filing context for SUPN.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

SUPN insider activity

Supernus Pharmaceuticals Inc

Score

Not evaluated

Pressure

Not evaluated

Filings

Buys / sells

0 / 0

Net value

Not evaluated

Insiders

Cluster

Not evaluated: the receipt-backed Form 4 snapshot could not be read

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

Form 4 evidence state

Not evaluated: the receipt-backed Form 4 snapshot could not be read.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in SUPN

Congress tracker Open ticker disclosure ledger →

Gilbert Ray Cisneros, Jr.Buy

SUPN · Transaction Mar 3, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000

Official filing ↗

Gilbert Ray Cisneros, Jr.Buy

Supernus Pharmaceuticals, Inc. - Common Stock · Transaction Mar 3, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000

Official filing ↗

Gilbert Ray Cisneros, Jr.Buy

SUPN · Transaction Dec 11, 2025 · Filed Jan 12, 2026 · $1,001 to $15,000

Official filing ↗

Gilbert Ray Cisneros, Jr.Buy

Supernus Pharmaceuticals, Inc. - Common Stock · Transaction Dec 11, 2025 · Filed Jan 12, 2026 · $1,001 to $15,000

Official filing ↗

Gilbert Ray Cisneros, Jr.Sell

SUPN · Transaction Oct 9, 2025 · Filed Nov 18, 2025 · $1,001 to $15,000

Official filing ↗

Federal contracts

SUPN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for SUPN in this window.

Lobbying spend

SUPN lobbying filings, year to date.

Registered lobbying filings matched to Supernus Pharmaceuticals Inc.

$130.0K

Refresh interval: 12hSource: LDA disclosure filings

Health Issues Medicare/MedicaidHealth Issues

Filing

$50.0K

SUPERNUS PHARMACEUTICALS FKA SAGE THERAPEUTICS

W STRATEGIES, LLC

Jan 20, 2026

Filing

$20.0K

SUPERNUS PHARMACEUTICALS INC

JEFFREY J. KIMBELL AND ASSOCIATES

Jul 20, 2026

Filing

$20.0K

SUPERNUS PHARMACEUTICALS INC

JEFFREY J. KIMBELL & ASSOCIATES, INC.

Apr 20, 2026

Analyst ratings

Sovereign unlock shows live analyst consensus for SUPN.

Options

Sovereign unlock shows live options positioning for SUPN.

Related tickers

Cross-references from this score page.

Apprentice · 1 rail

Similar headline score

Nearest public composite scores. Factor similarity requires Sovereign.

Follow $SUPN

Why is SUPN moving today?

What can move SUPN next.

SUPN overview

Related filings and maps

SUPN insider activity

SUPN contract awards, year to date.

SUPN lobbying filings, year to date.

Cross-references from this score page.

What can move SUPN next.

SUPN insider activity

Cross-references from this score page.